About ADMA Biologics (ADMA)
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ADMA
- CUSIP: N/A
- Previous Close: $4.64
- 50 Day Moving Average: $4.82
- 200 Day Moving Average: $5.52
- 52-Week Range: $4.34 - $8.85
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.27
- P/E Growth: 0.00
- Market Cap: $59.79M
- Outstanding Shares: 12,886,000
- Beta: 2.79
- Net Margins: -198.45%
- Return on Equity: -6,405.90%
- Return on Assets: -76.16%
- Debt-to-Equity Ratio: -92.07%
- Current Ratio: 2.76%
- Quick Ratio: 2.25%
Companies Related to ADMA Biologics:
Consensus Ratings for ADMA Biologics (NASDAQ:ADMA) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||1 Hold Rating, 1 Buy Rating|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||$13.00 (180.17% upside)|
Analysts' Ratings History for ADMA Biologics (NASDAQ:ADMA)
(Data available from 3/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|2/27/2017||Maxim Group||Set Price Target||Buy||$13.00||N/A|
|8/1/2016||Raymond James Financial, Inc.||Downgrade||Strong-Buy -> Market Perform||N/A|
Earnings History for ADMA Biologics (NASDAQ:ADMA)Earnings History by Quarter for ADMA Biologics (NASDAQ:ADMA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/11/2017|| || || || || || || || |
|11/10/2015||Q315||($0.39)||($0.48)||$1.50 million||$1.85 million||View||N/A|
|8/11/2015||Q215||($0.36)||($0.44)||$1.50 million||$1.30 million||View||N/A|
|5/12/2015||Q115||($0.38)||($0.37)||$1.50 million||$1.50 million||View||N/A|
Earnings Estimates for ADMA Biologics (NASDAQ:ADMA)
Current Year EPS Consensus Estimate: $-1.08 EPS
Next Year EPS Consensus Estimate: $-0.74 EPS
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for ADMA Biologics (NASDAQ:ADMA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ADMA Biologics (NASDAQ:ADMA)
Insider Ownership Percentage: 60.44%Insider Trades by Quarter for ADMA Biologics (NASDAQ:ADMA)
Institutional Ownership Percentage: 73.57%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/3/2016||Adam S Grossman||CEO||Buy||200,000||$6.50||$1,300,000.00|| |
|5/3/2016||Brian Lenz||CFO||Buy||2,500||$6.50||$16,250.00|| |
|5/3/2016||James Mond||CMO||Buy||770||$6.50||$5,005.00|| |
|5/3/2016||Jerrold B Grossman||Director||Buy||45,769||$6.50||$297,498.50|| |
|12/8/2015||Adam S. Grossman||CEO||Buy||500||$9.00||$4,500.00|| |
|12/7/2015||Jerrold B Grossman||Director||Buy||500||$9.01||$4,505.00|| |
|12/2/2015||Adam S Grossman||CEO||Buy||2,250||$9.15||$20,587.50|| |
|12/2/2015||Brian Lenz||CFO||Buy||1,000||$9.15||$9,150.00|| |
|12/2/2015||Jerrold B Grossman||Director||Buy||6,000||$9.16||$54,960.00|| |
|12/1/2015||Adam S Grossman||CEO||Buy||1,800||$9.17||$16,506.00|| |
|11/25/2015||Adam S Grossman||CEO||Buy||1,800||$9.18||$16,524.00|| |
|11/20/2015||Adam S Grossman||CEO||Buy||3,861||$9.21||$35,559.81|| |
|3/19/2015||Adam S Grossman||CEO||Buy||2,000||$8.50||$17,000.00|| |
|3/17/2015||Adam S Grossman||CEO||Buy||5,500||$7.98||$43,890.00|| |
|3/17/2015||Jerrold B Grossman||Director||Buy||500||$8.01||$4,005.00|| |
|3/16/2015||Adam S Grossman||CEO||Buy||8,800||$8.03||$70,664.00|| |
|3/16/2015||James Mond||CMO||Buy||1,250||$8.02||$10,025.00|| |
|3/16/2015||Lawrence P Guiheen||Director||Buy||1,000||$7.96||$7,960.00|| |
|3/13/2015||Eric I Richman||Director||Buy||3,500||$7.88||$27,580.00|| |
|9/12/2014||Adam S Grossman||CEO||Buy||4,300||$9.57||$41,151.00|| |
|8/22/2014||Adam S Grossman||CEO||Buy||1,000||$9.50||$9,500.00|| |
|8/14/2014||Adam S Grossman||CEO||Buy||2,100||$9.77||$20,517.00|| |
|6/18/2014||Adam S Grossman||CEO||Buy||1,875||$9.59||$17,981.25|| |
|5/22/2014||Adam S Grossman||CEO||Buy||4,226||$8.15||$34,441.90|| |
|5/15/2014||Adam S Grossman||CEO||Buy||13,400||$7.50||$100,500.00|| |
|5/14/2014||Brian Lenz||CFO||Buy||1,000||$7.50||$7,500.00|| |
|5/14/2014||James Mond||CMO||Buy||1,315||$7.60||$9,994.00|| |
|12/10/2013||Jerrold B Grossman||Director||Buy||3,650||$7.30||$26,645.00|| |
Headline Trends for ADMA Biologics (NASDAQ:ADMA)
Latest Headlines for ADMA Biologics (NASDAQ:ADMA)
|ADMA BIOLOGICS, INC. Financials (NASDAQ:ADMA)|
finance.yahoo.com - March 2 at 3:30 PM
|ADMA BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi (NASDAQ:ADMA)|
biz.yahoo.com - February 24 at 6:19 PM
|ADMA Biologics Reports Year End 2016 Financial Results, Accomplishments and Upcoming Milestones (NASDAQ:ADMA)|
finance.yahoo.com - February 24 at 6:19 PM
|ADMA BIOLOGICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:ADMA)|
biz.yahoo.com - February 18 at 7:49 AM
|Form 4 ADMA BIOLOGICS, INC. For: Feb 14 Filed by: LENZ BRIAN - StreetInsider.com (NASDAQ:ADMA)|
www.streetinsider.com - February 17 at 9:41 AM
|Form 4 ADMA BIOLOGICS, INC. For: Feb 14 Filed by: Guiheen Lawrence P. - StreetInsider.com (NASDAQ:ADMA)|
www.streetinsider.com - February 17 at 9:41 AM
|Blood Plasma Market 2017-2021 Key Regions Competitive Analysis (NASDAQ:ADMA)|
www.prnewswire.com - January 27 at 9:45 PM
|ADMA Biologics (ADMA) to Acquire Assets from Biotest Pharmaceuticals (NASDAQ:ADMA)|
www.streetinsider.com - January 25 at 1:43 AM
|DGAP-Adhoc: Biotest AG: Biotest verkauft US-Therapiegeschäft an ... - FinanzNachrichten.de (NASDAQ:ADMA)|
www.finanznachrichten.de - January 24 at 1:25 AM
|ADMA Biologics upgraded by Maxim Group (NASDAQ:ADMA)|
finance.yahoo.com - January 23 at 8:24 PM
|ADMA BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secu (NASDAQ:ADMA)|
biz.yahoo.com - January 23 at 8:24 PM
Frequently Asked Questions for ADMA Biologics (NASDAQ:ADMA)
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
How were ADMA Biologics' earnings last quarter?
ADMA Biologics Inc (NASDAQ:ADMA) issued its quarterly earnings data on Friday, August, 12th. The company reported ($0.50) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.11. ADMA Biologics had a negative return on equity of 6,405.90% and a negative net margin of 198.45%.
When will ADMA Biologics make its next earnings announcement?
ADMA Biologics is scheduled to release their next quarterly earnings announcement on Thursday, May, 11th 2017.
Where is ADMA Biologics' stock going? Where will ADMA Biologics' stock price be in 2017?
2 equities research analysts have issued twelve-month price objectives for ADMA Biologics' shares. Their forecasts range from $13.00 to $13.00. On average, they expect ADMA Biologics' share price to reach $13.00 in the next year.
Who owns ADMA Biologics stock?
ADMA Biologics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Broadfin Capital LLC (8.64%), Perceptive Advisors LLC (5.60%), FMR LLC (3.28%) and Franklin Resources Inc. (2.79%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, James Mond and Jerrold B Grossman.
Who bought ADMA Biologics stock? Who is buying ADMA Biologics stock?
ADMA Biologics' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond and Jerrold B Grossman.
How do I buy ADMA Biologics stock?
Shares of ADMA Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of ADMA Biologics stock cost?
One share of ADMA Biologics stock can currently be purchased for approximately $4.64.
ADMA Biologics (ADMA) Chart for Wednesday, March, 22, 2017